- Home
- ORIC vs NDMO Comparison
ORIC vs NDMO Comparison
Compare ORIC & NDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- NDMO
- Stock Information
- Founded
- ORIC 2014
- NDMO 2019
- Country
- ORIC United States
- NDMO United States
- Employees
- ORIC N/A
- NDMO N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- NDMO Trusts Except Educational Religious and Charitable
- Sector
- ORIC Health Care
- NDMO Finance
- Exchange
- ORIC Nasdaq
- NDMO Nasdaq
- Market Cap
- ORIC 362.9M
- NDMO N/A
- IPO Year
- ORIC 2020
- NDMO N/A
- Fundamental
- Price
- ORIC $11.10
- NDMO $10.12
- Analyst Decision
- ORIC Strong Buy
- NDMO
- Analyst Count
- ORIC 9
- NDMO 0
- Target Price
- ORIC $18.29
- NDMO N/A
- AVG Volume (30 Days)
- ORIC 949.2K
- NDMO 218.6K
- Earning Date
- ORIC 08-11-2025
- NDMO 01-01-0001
- Dividend Yield
- ORIC N/A
- NDMO 6.75%
- EPS Growth
- ORIC N/A
- NDMO N/A
- EPS
- ORIC N/A
- NDMO N/A
- Revenue
- ORIC N/A
- NDMO N/A
- Revenue This Year
- ORIC N/A
- NDMO N/A
- Revenue Next Year
- ORIC N/A
- NDMO N/A
- P/E Ratio
- ORIC N/A
- NDMO N/A
- Revenue Growth
- ORIC N/A
- NDMO N/A
- 52 Week Low
- ORIC $3.90
- NDMO $8.99
- 52 Week High
- ORIC $14.67
- NDMO $11.24
- Technical
- Relative Strength Index (RSI)
- ORIC 66.82
- NDMO 52.87
- Support Level
- ORIC $10.42
- NDMO $9.95
- Resistance Level
- ORIC $11.50
- NDMO $10.20
- Average True Range (ATR)
- ORIC 0.62
- NDMO 0.11
- MACD
- ORIC -0.03
- NDMO 0.00
- Stochastic Oscillator
- ORIC 83.30
- NDMO 51.52
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.